Title |
Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
|
---|---|
Published in |
Patient preference and adherence, November 2009
|
DOI | 10.2147/ppa.s5835 |
Pubmed ID | |
Authors |
Jennifer L Barton |
Abstract |
Significant advances in the treatment of rheumatoid arthritis (RA) have been made over the past 10 years with the introduction of biologic therapies, such as the TNF inhibitors. With these medications, many patients with RA have seen significant improvement in symptoms, function, and quality of life. However, with the introduction of the biologics, decision-making for this chronic disease that affects up to 1% of the population has become even more complex. Patient preferences for mode and frequency of administration, and for certain risks vs benefits as well as medication beliefs are central to uptake and adherence to these medications. This review examines the current literature on patient satisfaction, adherence, and preference for biologic therapy in RA. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 2 | 3% |
United Kingdom | 1 | 1% |
India | 1 | 1% |
Spain | 1 | 1% |
Unknown | 70 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 11 | 15% |
Student > Master | 10 | 13% |
Researcher | 9 | 12% |
Other | 8 | 11% |
Student > Doctoral Student | 7 | 9% |
Other | 21 | 28% |
Unknown | 9 | 12% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 36% |
Pharmacology, Toxicology and Pharmaceutical Science | 13 | 17% |
Agricultural and Biological Sciences | 10 | 13% |
Computer Science | 3 | 4% |
Economics, Econometrics and Finance | 3 | 4% |
Other | 7 | 9% |
Unknown | 12 | 16% |